A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer

Kartik Anand, Polly Niravath, Tejal Patel, Joe Ensor, Angel Rodriguez, Toniva Boone, Stephen T. Wong, Jenny C. Chang

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Chemotherapy eliminates most cancer cells except cancer stem cells. Chloroquine is a potential agent to target cancer stem cells. In this phase II trial for patients with breast cancer who were refractory to anthracycline-based chemotherapy, we combined chloroquine with taxane or taxane-like chemotherapy. The overall response rate of the combination was 45%, higher than the expected overall response rate of 30% with chemotherapy alone.

Original languageEnglish (US)
JournalClinical Breast Cancer
DOIs
StateAccepted/In press - 2020

Keywords

  • Cancer stem cells
  • Choloroquine
  • Docetaxel
  • Ixabepilone
  • Triple negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer'. Together they form a unique fingerprint.

Cite this